Table 2C.
Breast cancer risk in DTC survivors and/or DTC survivors given RAI: cohort and case-control studies from Europe.
| References, country | Study design, setting | Study period, length of FU (y), excluded if FU < x(y), Lost to FU (%) | Age range or mean age at DTC diagnosis (y) | DTC cases (TC), TC with RAI (TR) | BC cases (BT), BC with RAI (BR) | BC risk after TC, BC risk after RAI, risks (95% CI) | BC risk status after DTC | BC risk status after RAI |
|---|---|---|---|---|---|---|---|---|
| Osterlind et al. (38), Denmark | Cohort study, Denmark Cancer | 1943−1980, 5.9 y | TC 1,351 | BT 11 | SIR(BT) = 0.96 (0.76–1.20) | ⇔ | ||
| Hall et al. (39), Sweden | Cohort study, Swedish Cancer | 1958–1975, <1 y excluded | 49 y | TC 2,968 | BT 45 | SIR(BT) = 0.99 (0.72–1.33) | ⇔ | |
| Hall et al. (40), Sweden | Cohort study, Registry of 6 university hospitals | 1950–1975, 14–16 y, <2 y excluded | 5–75 y | TC 1,955, TR 834 |
BT 36, BR 9 |
SIR(BT) = 1.37 (0.91–2.00) FU > 10 y SIR(BT) = 1.75 (1.06–2.74), SIR(BR) = 0.74 (0.34–1.40), |
⇔ ⇑ |
⇔ |
| Hall et al. (41), Sweden | Case-control study, oncologic centers of 6 hospitals | 1950–1975, 50 y | 5–75 y | TC 1,955, TR 834 |
BR 36, no BR 107 |
O/R(BR) = 0.47 (0.21–1.08) | ⇔ | |
| Akslen and Glattre (42), Norway | Cohort study, Cancer Registry of Norway | 1955–1985, 8.8 y, <2 mo excluded | TC 2,720 | BT 33 | SIR(BT) = 1.03 (0.71–1.44) | ⇔ | ||
| Adjadj et al. (43), France | Case-control study, 3 French cancer centers | 1934–1995, 12 y, <2 y excluded, 21% lost to FU, 15% died | 42 y | TC 2.365 | BT 48 | SIR(BT) = 1.3 (1.0–1.7), SIR(BR) = 1.2 (0.2–6.2) | ⇑ | ⇔ |
| Berthe et al. (44), France | Cohort study, Basse-Normandie Cohort | 1960–1998, <1 y excluded | 47 y | TC 875 | BT 12 | SIR(BT) = 1.19 (0.62–2.08) | ⇔ | |
| Edhemovic et al. (45), Slovenia | Cohort study, Cancer Registry of Slovenia | 1971–1993, 5.2 y, <1 Mo excluded | 54.9 y | TC 894 | BT 4 | SIR(BT) = 1.12 (0.31–2.87) | ⇔ |
Some data may be absent in particular rows if the data were not reported in the publication. Numbers in parentheses represent 95% CIs. Up arrows (⇑) denote increased risk, horizontal arrows (⇔) denote no increased risk. Unless otherwise noted, the “DTC patients” group includes both patients receiving RAI and those not receiving RAI.
BC, breast cancer; CI, confidence interval; DTC, differentiated thyroid cancer; FU, follow-up; HR, hazard ratio; OR, odds ratio; RAI, radioiodine therapy; SIR, standardized incidence ratio.